Kurma Partners announced the first closing of its Growth Opportunities fund at €160 million. Meeting the demand of the growing maturity of the European biotech and healthtech ecosystem, this new fund
LaingBuisson News
Sander Slootweg, managing partner and co-founder of Forbion
European life sciences venture capital firm, Forbion, has announced the final close of its Forbion Growth 1 Fund at â¬360m (US$428m). The fund is focused on investing in late-stage life sciences companies, particularly European companies that develop novel therapies for areas of high medical need. The hard cap exceeds the original target size of â¬250m.
Forbion uses three strategies that aim to provide: private growth capital for clinical stage development assets, cross-over capital to companies aiming to pursue a public listing in the near-term, as well as capital injections that support existing under-valued public companies. It plans to take a leading position in its targets with an investment size of up to â¬35m per deal.
(0)
Fund launched in July 2020 invests in late-stage European life science companies
Fund now closed at the hard cap, with investors that include Pantheon, Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), the Belgian Growth Fund, New Waves Investments, Wealth Management Partners, KfW Capital and the European Investment Fund (EIF)
First three investments made from fund
Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I ( Forbion Growth I ) at the hard cap amount of EUR 360 million (USD 428 million). Forbion Growth I is focused on investing in late-stage European life sciences companies.
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million) financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.